InvestLog
Back to Market返回行情

ATHE Alterity Therapeutics Limited

USHealthcare
$5.43+0.93%ClosedMarket Cap: $49.2M

As of 2026-07-10 16:00

Why ATHE matters now

Alterity Therapeutics Limited (ATHE) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.43 with +0.93% on the session and $49.2M in market capitalization; recent performance reads 1-month +14.29% and YTD +58.44%.

The latest financial table shown here is Q2 2026, with revenue of $0.00, net income of $-9.4M, and EPS of $-0.54. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1.8%.

The latest indexable market news headline is "Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy" from GlobeNewsWire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Cunningham Ann Michelle filing . These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

—

PEG

—

P/B

2.25

P/S

34.05

EV/EBITDA

-4.05

DCF Value

$-13.63

FCF Yield

-1.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

96.8%

Operating Margin

-525.6%

Net Margin

-380.7%

ROE

-30.2%

ROA

-25.6%

ROIC

-31.3%

Financials

PeriodRevenueNet IncomeEPS
Q2 2026$0.00$-9.4M$-0.54
Q4 2025$3.8M$-5.0M$-0.42
FY 2025$5.4M$-12.1M$-1.14
Q2 2025$1.6M$-7.2M$-0.84

Analyst Ratings

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

Strong Buy: 1Buy: 1Hold: 0Sell: 0Strong Sell: 0

Trading Activity

Insider Trades

Cunningham Ann Michelledirector:
Sell2026-04-29
Stamler David Allendirector, officer: Chief Executive Officer
Sell2026-04-15
Stamler David Allendirector, officer: Chief Executive Officer
Sell2026-04-15
Stamler David Allendirector, officer: Chief Executive Officer
Sell2026-04-15
Stamler David Allendirector, officer: Chief Executive Officer
Sell2026-04-15

Related Stocks

ANVS
Annovis Bio, Inc.
$35.0M
BTAI
BioXcel Therapeutics, Inc.
$35.8M
DYAI
Dyadic International, Inc.
$29.0M
EVAX
Evaxion Biotech A/S
$22.7M
GBIO
Generation Bio Co.
$36.0M

Latest News

Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System AtrophyGlobeNewsWire · 2026-07-07
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular DisorderBenzinga · 2026-06-09
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System AtrophyGlobeNewsWire · 2026-06-09
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System AtrophyGlobeNewsWire · 2026-05-19
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System AtrophyGlobeNewsWire · 2026-05-11

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

AU

Exchange

—

Beta

-0.01

Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.